Identifying the structure-activity relationship of leelamine necessary for inhibiting intracellular cholesterol...

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Leelamine is an anticancer drug that inhibits intracellular cholesterol transport.
• Its mechanism involves lysosomal accumulation and disruption of cholesterol homeostasis.
• Cancer cells rely on cholesterol for critical functions, making its transport a therapeutic target.

Purpose of the Study:

• To investigate the structure-activity relationship of leelamine and identify key structural features for anticancer activity.
• To explore synthesized derivatives of leelamine and abietic acid for their therapeutic potential.
• To elucidate the molecular mechanism underlying the anticancer effects of these compounds.

Main Methods:

• Synthesis of leelamine and abietic acid derivatives.
• Evaluation of lysosomotropic properties and cellular cholesterol transport inhibition.
• In vitro and in vivo assessment of anticancer activity against melanoma xenografts.
• In silico studies to identify molecular targets.

Main Results:

• Active derivatives, like leelamine, possess a lysosomotropic moiety (e.g., amino group) for lysosomal accumulation.
• These compounds effectively inhibited intracellular cholesterol transport and melanoma tumor growth in vivo.
• No significant systemic toxicity was observed with the active derivatives.
• In silico analysis indicated binding to NPC1, inhibiting cholesterol export from lysosomes.

Conclusions:

• Lysosomotropic derivatives of leelamine and abietic acid are potent anticancer agents.
• Their efficacy stems from disrupting lysosomal cholesterol transport by inhibiting NPC1.
• These compounds represent promising candidates for novel cancer chemotherapeutics with a favorable safety profile.